News from this newspaper (Reporter Xu Wenjing, Correspondent Liu Qinghua) A few days ago, Fuchun Mountain Health City held the first Fuchun Mountain Health Industry Guidance Fund project review meeting for the project under discussion—the research and development project of small molecule targeted drugs for major diseases.
It is reported that the Fuchun Mountain Health Industry Guidance Fund is a guiding investment fund approved by the county government in September this year, led by the county finance bureau and the Health City Management Committee, and operated in a market-oriented manner. It aims to leverage financial funds and guide social capital investment. The key areas of health industry development in our county will support the green development of the health industry. Jiang Yu, member of the Party Committee and Deputy Director of Health City, introduced that the total size of the fund is 1 billion yuan, and the first phase is 200 million yuan. Focus on investment in new drug research and development, CRO and CDMO of drugs and medical devices, research and development and production of in vitro diagnostic reagents, and research and development and production of high-end medical devices. The fundraising, investment, post-investment management, and exit of the Guiding Fund operate in accordance with the principles of "government guidance, market operation, scientific decision-making, and risk prevention".
The project reviewed this time comes from Hangzhou Wutongshu Pharmaceutical Co., Ltd., which is a company specializing in the development of molecularly targeted drugs. For more than three years, the company has been relying on Shanghai WuXi AppTec New Drug Development Co., Ltd. and the R&D Center of Sichuan University to carry out medical technology research for major and difficult diseases such as lung cancer, kidney cancer, breast cancer, and liver cancer. Fang Suping, head of Hangzhou Wutongshu Pharmaceutical Co., Ltd., said: "The first review project involves 8 innovative drugs, 2 of which have obtained the national clinical approval on September 8 this year, and 2 have completed the application for the preclinical communication meeting. National approval is expected by the end of the year. The other 4 have already entered the preclinical development and clinical candidate compound optimization process.”
According to the fund management method, the evaluation committee will rely on the evaluation expert database of the Municipal Human Resources and Social Security Council to invite 5 judges, that is, 3 technical experts and 2 experts from venture capital institutions in each group, and conduct semi-closed defense roadshows with reference to the National Thousand Review. "The R&D team of this project is very good, and the company's business is developing rapidly, which is in line with expectations. Especially the quasi-drug molecules that have been screened have a relatively high positioning from the initial design to the subsequent process, and the future development prospects are worth looking forward to." The review expert group unanimously expressed.
In the next step, Fuchunshan Health City will further increase the guiding role of the industrial fund, give full play to the scale of the government guidance fund and the advantages in supporting industrial resources, realize the combination of government guidance and market-oriented operation, and provide strong support for the development of the big health medical industry. power.